Prescribing information


The first step of GILENYACONNECT, an assessment performed prior to treatment initiation to help you determine your patient’s suitability for GILENYA.

GILENYACONNECT expertise makes the pre-initiation check (the starting point of the programme) as easy and efficient as possible.

Once you have prescribed GILENYA and the patient has been enrolled, the GILENYACONNECT team will contact them to arrange an appointment.

Infographic detailing what the nurse and cardiac specialists involvement in the GILENYACONNECT programme are.


After these checks have been completed and reviewed by the team, you will receive a concise report of results to enable you to assess a patient’s suitability for GILENYA.

GILENYACONNECT is a healthcare service that is offered as a programme for patients prescribed GILENYA. It is not intended to replace the services of the patient’s NHS medical team.

ECG: electrocardiogram; Gd+: gadolinium enhancing; MRI: magnetic resonance imaging; RES: rapidly evolving severe; RRMS: relapsing remitting multiple sclerosis.

Indication: GILENYA is indicated as a single disease modifying therapy in highly active RRMS for the following groups of adult patients and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with ≥1 disease modifying therapy, or patients with RES RRMS defined by ≥2 disabling relapses in 1 year, and with 1 or more Gd+ lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.1


  1. GILENYA (fingolimod) Summary of Product Characteristics.
Rate this content: 
No votes yet
GIL19-C053d March 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]